This is a working overview of TP-7, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-20. Anything still debated is marked as such rather than presented as settled.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
=== Radioactive isotopes === The existence of isotopes was first suggested in 1913 by the radiochemist Frederick Soddy, based on studies of radioactive decay chains that indicated about 40 different species referred to as radioelements (i.e. radioactive elements) between uranium and lead, although the periodic table only allowed for 11 elements between lead and uranium inclusive. Several attempts to separate these new radioelements chemically had failed. For example, Soddy had shown in 1910 that mesothorium (later shown to be 228Ra), radium (226Ra, the longest-lived isotope), and thorium X (224Ra) are impossible to separate. Attempts to place the radioelements in the periodic table led Soddy and Kazimierz Fajans independently to propose their radioactive displacement law in 1913, to the effect that alpha decay produced an element two places to the left in the periodic table, whereas beta decay emission produced an element one place to the right. Soddy recognized that emission of an alpha particle followed by two beta particles led to the formation of an element chemically identical to the initial element but with a mass four units lighter and with different radioactive properties. Soddy proposed that several types of atoms (differing in radioactive properties) could occupy the same place in the table. For example, the alpha-decay of uranium-235 forms thorium-231, whereas the beta decay of actinium-230 forms thorium-230.
=== Over the counter === In 1998, in an unprecedented action in the United States, an American insurance company, Anthem Inc., petitioned the federal Food and Drug Administration to allow loratadine and two other antihistamines to be made available over the counter (OTC) while they were still protected by patents; the administration granted the request, which was not binding on manufacturers. In the United States, Schering-Plough made loratadine available over the counter in 2002. By 2015, loratadine was available over the counter in many countries.
It could possibly be extended to 10 days and prevent substantial cell damage by low temperature preservation methods. On the same day, a separate study reports new cryoprotectant solvents, tested with cells, that could preserve organs by the latter methods for much longer with substantially reduced damage.
Sources: en.wikipedia.org
In ion chromatography, the interaction of the solute ions and the stationary phase based on their charges determines which ions will bind and to what degree. When the stationary phase features positive groups which attracts anions, it is called an anion exchanger; when there are negative groups on the stationary phase, cations are attracted and it is a cation exchanger. The attraction between ions and stationary phase also depends on the resin, organic particles used as ion exchangers. Each resin features relative selectivity which varies based on the solute ions present who will compete to bind to the resin group on the stationary phase. The selectivity coefficient, the equivalent to the equilibrium constant, is determined via a ratio of the concentrations between the resin and each ion, however, the general trend is that ion exchangers prefer binding to the ion with a higher charge, smaller hydrated radius, and higher polarizability, or the ability for the electron cloud of an ion to be disrupted by other charges. Despite this selectivity, excess amounts of an ion with a lower selectivity introduced to the column would cause the lesser ion to bind more to the stationary phase as the selectivity coefficient allows fluctuations in the binding reaction that takes place during ion exchange chromatography. Following table shows the commonly used ion exchangers.
== Diagnosis == The diagnosis of a migraine is based on signs and symptoms. A headache calendar is a useful diagnostic tool for tracking the date, duration, and symptoms of headaches. Migraines can be classified by whether the patient experiences an aura (MA) or not (MO) and headache frequency (episodic or chronic). According to the International Classification of Headache Disorders (ICHD-3), migraine diagnosis is primarily clinical and based on identifying characteristic patterns of headache features and associated symptoms rather than laboratory or imaging findings. Neuroimaging tests are not necessary to diagnose migraine, but may be used to find other causes of headaches in those whose examination and history do not confirm a migraine diagnosis. The American Headache Society's guideline recommends neuroimaging only when "red-flag" symptoms or abnormal neurological findings are present, noting that routine imaging is unnecessary for patients who already meet clinical criteria for migraine. The diagnosis of migraine without aura, according to the International Headache Society, can be made according to the "5, 4, 3, 2, 1 criteria", which is as follows:
== Epidemiology == Calciphylaxis most commonly occurs in patients with end-stage renal disease who are on hemodialysis or who have recently received a kidney transplant. When reported in patients without end-stage renal disease (such as in earlier stages of chronic kidney disease or in normal kidney function), it is called non-uremic calciphylaxis by Nigwekar et al. Non-uremic calciphylaxis has been observed in patients with primary hyperparathyroidism, breast cancer (treated with chemotherapy), liver cirrhosis (due to hazardous alcohol use), cholangiocarcinoma, Crohn's disease, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Calciphylaxis, regardless of etiology, has been reported at an incidence of 35 in 10,000 dialysis patients per year in the United States, 4 in 10,000 patients in Germany, and less than 1 in 10,000 patients in Japan. It is unknown whether the higher incidence in the United States is due to genuinely higher incidence or due to underreporting in other countries. Annual incidence in kidney transplant patients and in non-uremic calciphylaxis patients is also unknown. The median age of patients at diagnosis of calciphylaxis is 60 years and the majority of these patients are women (60-70%). The location of lesions, central (located on the trunk) or peripheral (located on the extremities), is dependent on several risk factors. Central lesions are associated with younger patients, patients with a higher body mass index, and a higher risk of death than those who have peripheral-only lesions.
The Artificial Intelligence Cold War (AI Cold War) is a narrative in which geopolitical tensions between the United States of America (USA) and the People's Republic of China (PRC) could lead to a Second Cold War waged in the area of artificial intelligence technology rather than in the areas of nuclear capabilities or ideology. The context of the AI Cold War narrative is the AI arms race, which involves a build-up of military capabilities using AI technology by the US and China and the usage of increasingly advanced semiconductors which power those capabilities. According to a February 2019 publication by the Center for a New American Security, General Secretary of the Chinese Communist Party Xi Jinping – believes that being at the forefront of AI technology will be critical to the future of China's global military and economic power competition.
Sources: en.wikipedia.org
But the judge's ruling adds an additional $42.3 million, meaning the men will share about 17 percent of the money the whistle-blowers helped bring in. The total award, $52 million, is considered to be the largest whistleblower award to date.
Phthalimide is the organic compound with the formula C6H4(CO)2NH. It is the imide derivative of phthalic anhydride. It is a sublimable white solid that is slightly soluble in water but more so upon addition of base. It is used as a precursor to other organic compounds as a masked source of ammonia.
== Research == A study on 7-OH-MIT's safety was unable to identify a lethal dose orally due to a lack of deaths occurring. In a later part of the same study they found both mitragynine and 7-OH-MIT to be able to cause respiratory depression when given intravenously. This same study also showed seizures in many of the surviving mice from the mitragynine group. 7-OH-MIT has been described as a "prototypical" compound to develop a new generation of opioids with an improved safety profile. In an electrical stimulation test using guinea-pig ileum, 7-OH-MIT showed opioid agonist potency 13-fold higher than morphine.
== Adverse effects == Common adverse drug reactions (≥ 1% of people) include diarrhea, nausea, vomiting, joint pain; infections, leukopenia, or anemia reflect the immunosuppressive and myelosuppressive nature of the drug. Mycophenolate sodium is also commonly associated with fatigue, headache, cough and/or breathing issues. Intravenous (IV) administration of mycophenolate mofetil is also commonly associated with thrombophlebitis and thrombosis. Infrequent adverse effects (0.1–1% of people) include esophagitis, gastritis, gastrointestinal tract hemorrhage, and/or invasive cytomegalovirus (CMV) infection. More rarely, pulmonary fibrosis or various neoplasia occur: melanoma, lymphoma, other malignancies having an occurrences of 1 in 20 to 1 in 200, depending on the type, with neoplasia in the skin being the most common site. Several cases of pure red cell aplasia (PRCA) have also been reported. The U.S. Food and Drug Administration (FDA) issued an alert that people are at increased risk of opportunistic infections, such as activation of latent viral infections, including shingles, other herpes infections, cytomegalovirus, and BK virus associated nephropathy. In addition the FDA is investigating 16 people that developed a rare neurological disease while taking the drug. This is a viral infection known as progressive multifocal leukoencephalopathy; it attacks the brain and is usually fatal.
Bancroft, EA (October 2007). "Antimicrobial resistance: it's not just for hospitals". JAMA. 298 (15): 1803–1804. doi:10.1001/jama.298.15.1803. PMC 2536104. PMID 17940239. Larson, E (2007). "Community factors in the development of antibiotic resistance". Annual Review of Public Health. 28 (1): 435–447. doi:10.1146/annurev.publhealth.28.021406.144020. PMID 17094768.
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.